Oxymetholone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Oxymetholone

Oxymetholone (Anadrol), is a synthetic anabolic steroid developed by Syntex in 1960. Its primary clinical applications include treatment of osteoporosis and anaemia, as well as stimulating muscle growth in undernourished or underdeveloped patients. The drug was approved for human use by the FDA. However, later non-steroidal drugs such as Epogen were developed and proven to be more effective as a treatment for anaemia and osteoporosis without the side-effects of oxymtholone. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

The drug remained available despite this, and eventually found a new use in treating HIV wasting syndrome. While classified as a Schedule III drug under the Controlled Substances Act, it remains available via prescription as Anadrol (registered as a trademark of Unimed Pharmaceuticals.)

Presented most commonly as a 50mg tablet, Oxymetholone is the strongest androgenic steroid available. Similarly, it also poses the greatest risk of side effects of any steroid. Despite very low binding affinity with the androgen receptor, oxymetholone is highly effective in promoting extensive gains in body mass, mostly by greatly improving muscular water retention. For this reason, it is often used illegally by bodybuilders and athletes. Many athletes also use Oxymetholone as a method of protection for the joints under heavy loads. Due to the high water retention users experience from this drug, it similarily lubricates the joints and helps protect them from injury.

Side effects

The side-effects of short-term use of the drug itself include nausea, bloating, acne, and masculinising effects such as deepening of the voice, growth of facial hair and clitoral hypertrophy . In addition, oxymetholone is readily aromatized by aromatase to form a progestagen, and unless selective estrogen receptor modulators such as Nolvadex or Clomid are taken in conjunction with the drug, there is a significant risk of the appearance of estrogenic effects such as gynaecomastia over time. Because of its 17α-alkylated structure, oxymetholone is highly hepatoxic. Long term use of the drug can cause a variety of serious ailments, including hepatitis, liver cancer, and cirrhosis. It is very dangerous to take Oxymetholone in high dosages for periods of time exceeding six weeks, and is commonly used by bodybuilders during the start of a steroid cycle to help gain mass and increase serum levels of androgens quickly.

Use with other steroids

To further increase its effectiveness as an anabolic agent, bodybuilders typically stack (see steroid stack) oxymetholone with other anabolic steroids. Since it is already a very potent androgen, many users will combine it with drugs such as nandrolone, Boldenone and Oxandrolone to further their gains.

Read more at Wikipedia.org


[List your site here Free!]


Peliosis Hepatis Associated With Lymphoplasmacytic Lymphoma: An Autopsy Case Report
From Archives of Pathology & Laboratory Medicine, 11/1/04 by Corpa, Marcus V N

A 72-year-old man with no previous history of liver disease was admitted to our university hospital with severe dyspnea, edema of the lower limbs, and weight loss. Within a few days of hospitalization, he died due to severe bleeding in the upper digestive tract. At autopsy, the liver displayed typical gross features of peliosis hepatis. In addition, a diffuse infiltration of liver, spleen, bone marrow, and lymph nodes by lymphoplasmacytic lymphoma was disclosed by light microscopy. In the liver, the neoplastic cells partially filled the peliotic cavities. Peliosis hepatis is a rare liver disease characterized by multiple blood-filled, dilated cavities within the liver parenchyma. Association of lymphoplasmacytic lymphoma and peliosis hepatis has rarely been reported in the literature. The pathologic findings of such an unusual association and a review of the literature are presented.

(Arch Pathol Lab Med. 2004;128:1283-1285)

Peliosis hepatis is characterized by the presence of blood-filled cavities in the liver1 and was first described by Wagner in 1861. Various unrelated conditions have been reported to be associated with peliosis hepatis, the most important of them being the administration of steroid hormones.2 Other conditions include Castleman disease,3 Hodgkin lymphoma,4 malnutrition,5 Bartonella species infection,6 hairy cell leukemia,7 malignant histiocytosis,8 and renal transplantation.9,10 We report an autopsy case of peliosis hepatis in a patient affected by lymphoplasmacytic lymphoma. We found only 2 previous reports of a similar association in the literature.11,12

REPORT OF A CASE

A 72-year-old man presented to the emergency room with severe dyspnea at mild effort, edema of the lower limbs, and a 4-kg weight loss within the preceding 20 days. He had no known history of chronic obstructive lung disease and had no past medical history of liver disease or steroid hormone use. On admission, routine hematological laboratory tests included an erythrocyte count of 1.6 × 10^sup 6^/µL; hemoglobin, 6.4 g/dL; and white blood cell count, 8.89 × 10^sup 6^/µL. A differential count showed 44% neutrophils, 42% lymphocytes, 13.4% monocytes, 0.3% eosinophils, and 0.6% basophils. No atypical lymphocytes were detected in the peripheral blood smear. Serum aspartate aminotransferase and alanine transferase levels were within normal reference ranges. A roentgenogram of the thorax revealed a large mediastinal mass, suggestive of lymph node enlargement. During hospitalization, the patient experienced severe bleeding in the upper digestive tract, with consequent hemorrhagic shock. He received several erythrocyte-concentrated blood transfusions without response and died on the 12th internment day.

MATERIALS AND METHODS

The tissue samples were fixed in 10% buffered formalin and embedded in paraffin. Four-micrometer-thick sections from the paraffin blocks were stained with hematoxylin-eosin. Masson trichrome and silver stains were also prepared. Immunohistochemistry was performed using the avidin-biotin-peroxidase method after heat-induced antigen retrieval. Stains for CD3 (clone PS1, Novocastra, Newcastle upon Tyne, United Kingdom), CDS (Novocastra), CD20 (clone L26, Dako Corporation, Carpinteria, Calif), CD138 (clone B-B4 Serotec, Oxford, United Kingdom), κ light chain, and λ light chain, as well as immunoglobulin (Ig) M, IgG, IgA, and IgD heavy chains (Dako) were performed.

PATHOLOGIC FINDINGS

At autopsy, the main macroscopic findings were hepatomegaly (3205 g), splenomegaly (295 g), and mediastinal adenomegaly. The liver contained many small empty spaces intermingled and very often mixed to confluent hemorrhagic dots (Figure 1).

Microscopically, the liver displayed numerous dilated, randomly distributed, blood-filled spaces, bordered by atrophie liver cell plates, characterizing peliosis hepatis (Figure 2). The cavities were also irregularly filled with a monotonous dense infiltrate of neoplastic small lymphocytes, most with lymphoplasmacytic features, characterized by small round nuclei with granular chromatin and light eosinophilic cytoplasm (Figure 3). The same neoplastic lymphoid infiltrate was also present in mediastinal lymph nodes, spleen, and bone marrow.

Immunohistochemistry revealed diffuse positivity of the neoplastic cells for CD20 (Figure 4), κ light chain, and IgG heavy chain, and faint focal positivity for CD138. The immunostains for CD3, CDS, λ light chains, IgM, IgD, and IgA heavy chains were all negative. The combination of morphologic and immunohistochemical features of the neoplastic cells were diagnostic of lymphoplasmacytic lymphoma.

COMMENT

Peliosis is defined as the presence of cystic blood-filled spaces in the liver, spleen, and lymph nodes, as well as in other organs.1 When occurring in the liver, it is referred to as peliosis hepatis. It is usually asymptomatic, frequently discovered only as a result of abnormal liver function tests. Liver rupture, either spontaneous or after minor trauma, can occur, albeit rarely. Of the different conditions associated with the onset of peliosis hepatis, the most common is the use of steroid hormones.2 Other conditions include Castleman disease,3 Hodgkin disease,4 malnutrition,5 Bartonella species infections in immunosuppressed patients (especially those with acquired immunodeficiency syndrome),6 hairy cell leukemia,7 malignant histiocytosis,8 and renal transplantation, presumably secondary to cyclosporine and azathioprine therapy.13 Our case of peliosis hepatitis was associated with massive liver infiltration by lymphoplasmacytic lymphoma.

Lymphoplasmacytic lymphoma is a rare B-cell neoplasm that accounts for only 1.5% of nodal lymphomas.13 When a monoclonal IgM serum paraprotein is present, the designation Waldenström macroglobulinemia is applicable. This neoplasm usually involves bone marrow, lymph nodes, and spleen.13 It occurs predominantly in older individuals and exhibits a slight male predominance. In the Revised European-American Lymphoma Classification clinical study, the mean age was 63 years and 53% of the patients were male.14 Microscopically, the neoplastic cells are small lymphocytes with plasmacytic features, lacking expression of CD5 and CD23, with strong expression of B-cell markers, as well as surface and cytoplasmic immunoglobulin. Differential diagnosis with plasmacytoma/multiple myeloma based on pure morphologic grounds is sometimes difficult. In these cases, immunohistochemistry is a very helpful tool. The strong diffuse positivity of the neoplastic cells for CD20, with only focal positivity for CD138, associated with the morphologic and clinical features, helped to exclude the diagnosis of plasmacytoma/multiple myeloma in the present case.

To the best of our knowledge, only 2 previous reports of peliosis hepatis in association with lymphoplasmacytic lymphoma have been published. Ginestal-Cruz et al11 reported a case of Waldenström macroglobulinemia that presented as a bleeding duodenal ulcer. After several months of therapy with oxymetholone, peliosis was diagnosed through a fine-needle liver biopsy. The biopsy disclosed a portal infiltrate by lymphoma cells, surrounded by typical peliotic cavities, which did not contain neoplastic cells. Voinchet et al12 reported a case of a 54-year-old woman with persistent elevated levels of serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Liver biopsy demonstrated peliosis without infiltration by neoplastic cells.

The present case differs from the 2 aforementioned cases by its unique pattern of infiltration, with the presence of neoplastic cells inside the peliotic cavities. The case reported by Ginestal-Cruz et al11 was most probably due to the therapy with oxymetholone, a steroid known to induce peliosis both in vitro and in vivo,15 although neoplastic cells were present in the portal tracts. On the other hand, in the case reported by Voinchet et al,12 the lesions most probably resulted from liver damage by circulating immunoglobulins, as demonstrated by the presence of κ-chain deposits along the sinusoids.

The unusual sinusoidal pattern of infiltration by neoplastic cells seen in the present case in association with peliosis hepatis, to our knowledge has only been reported previously in hairy cell leukemia7 and was attributed to the presence of VCAM-1 in the wall of the hepatic sinusoids. In the few published cases of lymphoma-associated peliosis hepatis, such a pattern of infiltration was absent.4,11,12

The pathogenesis of peliosis hepatis is still not well understood. Possible mechanisms include obstruction of the sinusoidal blood flow, as in neoplastic infiltration, and sinusoidal wall damage by infectious agents or drugs, as in Bartonella infections and steroid hormone administration. The loss of reticulin fibers in the wall of the peliotic cavities is demonstrated in most situations, supporting the concept that some kind of damage to its structure is the cause of the lesions, but it has not been clearly verified yet.

Previous reports of peliosis hepatis arising in patients with Castleman disease of plasma cell type in which monoclonal gammaglobulinemia was present3 also point toward a possible role of abnormally high concentrations of circulating immunoglobulins in the pathogenesis of peliosis hepatis. The high concentration of serum immunoglobulins probably exerts its effect through increasing blood viscosity and decreasing sinusoidal blood flow.11 In 1 case,3 although photomicrographs were not shown, plasma cells were present in both the portal tracts and sinuses, similar to our case. One could hypothesize that the cells present in the sinusoids in that case and in our case could be the source of the lesions either obstructing the blood flow through the sinusoids or damaging its walls.

The pathogenesis of peliosis hepatis is still in question. The heterogeneity of the clinical settings in which it develops and its low frequency are factors that make it difficult to establish a single model of pathogenesis. Our case of peliosis hepatis in association with liver infiltration by a lymphoplasmacytic lymphoma is, to the best of our knowledge, the third report of such an association and the first with massive presence of neoplastic cells inside the peliotic cavities. The histopathologic features of the present case suggest a possible role of the neoplastic cells themselves as causative agents of liver damage in peliosis hepatis. Furthermore, this case also emphasizes the strong relationship between peliosis hepatis and malignant neoplasms, especially hematologic neoplasms, which can be helpful in a clinical setting when dealing with a case of peliosis hepatis.

References

1. Wanless IR. Vascular disorders. In: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, eds. Pathology of the Liver. New York, NY: Churchill Livingstone; 2002:539-573.

2. Nadell J, Kosek J. Peliosis hepatis: twelve cases associated with oral androgen therapy. Arch Palhol Lab Med. 1977;101:405-410.

3. Sherman D, Ramsay B, Theodorou NA, et al. Reversible plane xanthoma, vasculitis, and peliosis hepatis in giant lymph node hyperplasia (Castleman's disease): a case report and review of the cutaneous manifestations of giant lymph node hyperplasia. J Am Acad Dermatol. 1992;26:105-109.

4. Bhaskar KV, Joshi K, Banerjee CK, et al. Peliosis hepatis in Hodgkin's disease: an infrequent association. Am J Gastroenterol. 1990;85:628-629.

5. Simon DM, Krause R, Calambos JT. Peliosis hepatis in a patient with marasmus. Gastroenterology. 1988;95:805-809.

6. Perochka LA, Geaghan SM, Yen TSB, et al. Clinical and pathological features of bacillary peliosis hepatis in association with human immunodeficiency virus infection. N Engl J Med. 1990;323:1581-1586.

7. Zafrani ES, Degos F, Guigui B, et al. The hepatic sinusoid in hairy cell leukemia: an ultrastructural study of 12 cases. Hum Palhol. 1987;18:801-807.

8. Fine KD, Solano M, Polter DE, et al. Malignant histiocytosis in a patient presenting with hepatic dysfunction and peliosis hepatis. Am J Gastroenterol. 1995;90:485-488.

9. Izumi S, Nishiuchi M, Kameda Y, et al. Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases. J Hepatol. 1994;20:129-137.

10. Cavalcanti R, Pol S, Carnot F, et al. Impact and evolution of peliosis hepatis in renal transplant recipients. Transplantation. 1994;58:31 5-316.

11. Ginestal-Cruz A, Correia JP, Batista A, et al. Recurrent upper gastro-intestinal bleeding, duodenal and gastric ulcer and peliosis hepatis in a patient with Waldenstrom's macroglobulinemia. Acta Med Port. 1979;1:721-727.

12. Voinchet O, Degott C, Scoazec JY, et al. Peliosis hepatis, nodular regenerative hyperplasia of the liver, and light-chain deposition in a patient with Waldenstrom's macroglobulinemia. Gastroenterology. 1988;95:482-48b.

13. Berger F, Isaacson PG, Piris MA, et al. Lymphoplasmacytic lymphoma/Wäldenström macroglobulinemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:132-134. World Health Organization Classification of Tumours; vol 3.

14. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.

15. Pavlatos AM, Fultz O, Monberg MJ, et al. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther. 2001;23:789-801.

Marcus V. N. Corpa, MD; Maura M. Bacchi, MD; Carlos E. Bacchi, MD; Kunie I. R. Coelho, MD

Accepted for publication June 29, 2004.

From the Department of Pathology, Faculdade de Medicina de Botucatu, State University of Sao Paulo, Botucatu, Sao Paulo, Brazil.

The authors have no relevant financial interest in the products or companies described in this article.

Reprints: Marcus V. N. Corpa, MD, Rua Azevedo Scares 2018, Tatuape, Sao Paulo-SP, Brazil 03322-002 (e-mail: mvncorpa@terra.com.br).

Copyright College of American Pathologists Nov 2004
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Oxymetholone
Home Contact Resources Exchange Links ebay